Literature DB >> 23649415

Atypical femoral fractures associated with long-term bisphosphonate use.

Soumya Chatterjee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23649415      PMCID： PMC3787173          DOI： 10.1503/cmaj.121698

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Atypical femoral fracture risk in patients treated with bisphosphonates.

Authors:  Douglas C Bauer
Journal:  Arch Intern Med       Date:  2012-06-25

2.  Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.

Authors:  Raphael P H Meier; Thomas V Perneger; Richard Stern; René Rizzoli; Robin E Peter
Journal:  Arch Intern Med       Date:  2012-06-25

3.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272
  3 in total
  1 in total

1.  Caveats of bisphosphonate abuse.

Authors:  Sanjay Agarwala; Vikas M Agashe; Vivek Shetty; Ganesh Mohrir; Pradeep Moonot
Journal:  Indian J Orthop       Date:  2016 Jul-Aug       Impact factor: 1.251
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.